

# Stefan W Krause

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4913613/publications.pdf>

Version: 2024-02-01

91  
papers

8,386  
citations

57719

44  
h-index

48277

88  
g-index

93  
all docs

93  
docs citations

93  
times ranked

11250  
citing authors

#	ARTICLE	IF	CITATIONS
1	Inhibitory effect of tumor cell-derived lactic acid on human T cells. <i>Blood</i> , 2007, 109, 3812-3819.	0.6	1,361
2	Liposomal Amphotericin B as Initial Therapy for Invasive Mold Infection: A Randomized Trial Comparing a High-Loading Dose Regimen with Standard Dosing (AmBiLoad Trial). <i>Clinical Infectious Diseases</i> , 2007, 44, 1289-1297.	2.9	663
3	Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. <i>Lancet Haematology</i> , 2016, 3, e217-e227.	2.2	442
4	Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. <i>Lancet Oncology</i> , 2015, 16, 1691-1699.	5.1	347
5	Tolerability-Adapted Imatinib 800 mg/d Versus 400 mg/d Versus 400 mg/d Plus Interferon- $\gamma$ in Newly Diagnosed Chronic Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2011, 29, 1634-1642.	0.8	307
6	Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IV. <i>Journal of Clinical Oncology</i> , 2014, 32, 415-423.	0.8	271
7	Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. <i>Lancet Haematology</i> , 2017, 4, e510-e523.	2.2	258
8	Treatment of Colon and Lung Cancer Patients with ex Vivo Heat Shock Protein 70-Peptide-Activated, Autologous Natural Killer Cells. <i>Clinical Cancer Research</i> , 2004, 10, 3699-3707.	3.2	224
9	PU.1 and Interferon Consensus Sequence-binding Protein Regulate the Myeloid Expression of the Human Toll-like Receptor 4 Gene. <i>Journal of Biological Chemistry</i> , 2000, 275, 9773-9781.	1.6	217
10	Transcriptional Regulation of CHI3L1, a Marker Gene for Late Stages of Macrophage Differentiation. <i>Journal of Biological Chemistry</i> , 2003, 278, 44058-44067.	1.6	212
11	Differential screening identifies genetic markers of monocyte to macrophage maturation. <i>Journal of Leukocyte Biology</i> , 1996, 60, 540-545.	1.5	187
12	Eight Cycles of Escalated-Dose BEACOPP Compared With Four Cycles of Escalated-Dose BEACOPP Followed by Four Cycles of Baseline-Dose BEACOPP With or Without Radiotherapy in Patients With Advanced-Stage Hodgkin's Lymphoma: Final Analysis of the HD12 Trial of the German Hodgkin Study Group. <i>Journal of Clinical Oncology</i> , 2011, 29, 4234-4242.	0.8	183
13	Species-specific Regulation of Toll-like Receptor 3 Genes in Men and Mice. <i>Journal of Biological Chemistry</i> , 2003, 278, 21502-21509.	1.6	174
14	Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML Study IV. <i>Blood</i> , 2015, 126, 42-49.	0.6	171
15	Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). <i>Annals of Hematology</i> , 2018, 97, 197-207.	0.8	162
16	Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. <i>Haematologica</i> , 2009, 94, 113-122.	1.7	160
17	Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial. <i>Lancet</i> , 2015, 385, 1418-1427.	6.3	154
18	Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group. <i>Journal of Clinical Oncology</i> , 2019, 37, 2835-2845.	0.8	151

#	ARTICLE	IF	CITATIONS
19	Adoptive immunotherapy of cancer using monocyte-derived macrophages: rationale, current status, and perspectives. <i>Journal of Leukocyte Biology</i> , 1998, 64, 419-426.	1.5	127
20	Comparison of Automated Differential Blood Cell Counts From Abbott Sapphire, Siemens Advia 120, Beckman Coulter DxH 800, and Sysmex XE-2100 in Normal and Pathologic Samples. <i>American Journal of Clinical Pathology</i> , 2013, 139, 641-650.	0.4	103
21	Pioglitazone and rofecoxib combined with angiostatically scheduled trofosfamide in the treatment of far-advanced melanoma and soft tissue sarcoma. <i>Cancer</i> , 2004, 101, 2247-2256.	2.0	97
22	Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib. <i>Haematologica</i> , 2014, 99, 1441-1447.	1.7	97
23	Ex Vivo-activated Human Macrophages Kill Chronic Lymphocytic Leukemia Cells in the Presence of Rituximab: Mechanism of Antibody-dependent Cellular Cytotoxicity and Impact of Human Serum. <i>Journal of Immunotherapy</i> , 2006, 29, 388-397.	1.2	94
24	Primary prophylaxis of invasive fungal infections in patients with haematologic malignancies. 2014 update of the recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. <i>Annals of Hematology</i> , 2014, 93, 1449-1456.	0.8	88
25	Therapy with antifungals decreases the diagnostic performance of PCR for diagnosing invasive aspergillosis in bronchoalveolar lavage samples of patients with haematological malignancies. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 2260-2267.	1.3	85
26	Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?. <i>Blood</i> , 2020, 136, 823-830.	0.6	85
27	Prognosis of patients with primary central nervous system lymphoma after high-dose chemotherapy followed by autologous stem cell transplantation. <i>Haematologica</i> , 2013, 98, 765-770.	1.7	82
28	<i>CEBPA</i> mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome. <i>Blood</i> , 2022, 139, 87-103.	0.6	82
29	Active DNA demethylation in human postmitotic cells correlates with activating histone modifications, but not transcription levels. <i>Genome Biology</i> , 2010, 11, R63.	13.9	75
30	The Treatment of Patients With Disseminated Malignant Melanoma by Vaccination With Autologous Cell Hybrids of Tumor Cells and Dendritic Cells. <i>Journal of Immunotherapy</i> , 2002, 25, 421-428.	1.2	74
31	Carboxypeptidase M Is Identical to the MAX.1 Antigen and Its Expression Is Associated with Monocyte to Macrophage Differentiation. <i>Journal of Biological Chemistry</i> , 1995, 270, 15644-15649.	1.6	71
32	High-Dose Cytarabine Consolidation With or Without Additional Amsacrine and Mitoxantrone in Acute Myeloid Leukemia: Results of the Prospective Randomized AML2003 Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 2094-2102.	0.8	71
33	Epidemiology of invasive aspergillosis and azole resistance in patients with acute leukaemia: the SEPIA Study. <i>International Journal of Antimicrobial Agents</i> , 2017, 49, 218-223.	1.1	71
34	Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML. <i>Annals of Hematology</i> , 2015, 94, 2015-2024.	0.8	67
35	Diagnosing pulmonary aspergillosis in patients with hematological malignancies: a multicenter prospective evaluation of an <i>Aspergillus</i> PCR assay and a galactomannan ELISA in bronchoalveolar lavage samples. <i>European Journal of Haematology</i> , 2012, 89, 120-127.	1.1	63
36	Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV. <i>Annals of Hematology</i> , 2014, 93, 71-80.	0.8	60

#	ARTICLE	IF	CITATIONS
37	Relapsed Hodgkin Lymphoma in Older Patients: A Comprehensive Analysis From the German Hodgkin Study Group. <i>Journal of Clinical Oncology</i> , 2013, 31, 4431-4437.	0.8	57
38	Monocyte-Derived Human Macrophages Mediate Anergy in Allogeneic T Cells and Induce Regulatory T Cells. <i>Journal of Immunology</i> , 2006, 177, 2691-2698.	0.4	54
39	Hybrid Cell Vaccination in Metastatic Melanoma. <i>Journal of Immunotherapy</i> , 2004, 27, 147-155.	1.2	51
40	CCAAT Enhancer-binding Protein $\beta$ Regulates Constitutive Gene Expression during Late Stages of Monocyte to Macrophage Differentiation. <i>Journal of Biological Chemistry</i> , 2007, 282, 21924-21933.	1.6	51
41	Label-Free High-Throughput Leukemia Detection by Holographic Microscopy. <i>Advanced Science</i> , 2018, 5, 1800761.	5.6	50
42	High-risk additional chromosomal abnormalities at low blast counts herald death by CML. <i>Leukemia</i> , 2020, 34, 2074-2086.	3.3	50
43	Measurement of immature platelets with Abbott CD-Sapphire and Sysmex XE-5000 in haematology and oncology patients. <i>Clinical Chemistry and Laboratory Medicine</i> , 2013, 51, 2125-2131.	1.4	47
44	Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial. <i>Leukemia</i> , 2022, 36, 1870-1878.	3.3	47
45	Comparative Analysis of Dendritic Cells Derived from Blood Monocytes or CD34+ Hematopoietic Progenitor Cells. <i>Immunobiology</i> , 1998, 198, 501-513.	0.8	44
46	Three-dimensional co-culture of human monocytes and macrophages with tumor cells: Analysis of macrophage differentiation and activation. , 1996, 66, 645-652.		40
47	Analysis of the Immune Response against Tetanus Toxoid: Enumeration of Specific T Helper Cells by the Elispot Assay. <i>Immunobiology</i> , 2002, 205, 282-289.	0.8	40
48	Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial. <i>Leukemia</i> , 2021, 35, 2517-2525.	3.3	40
49	Mature But Not Immature Fas Ligand (CD95L)-Transduced Human Monocyte-Derived Dendritic Cells Are Protected from Fas-Mediated Apoptosis and Can Be Used as Killer APC. <i>Journal of Immunology</i> , 2003, 170, 5406-5413.	0.4	36
50	Empirical antimicrobial monotherapy in patients after high-dose chemotherapy and autologous stem cell transplantation: a randomised, multicentre trial. <i>British Journal of Haematology</i> , 2005, 130, 265-270.	1.2	35
51	Retinoic Acid Inhibits Monocyte to Macrophage Survival and Differentiation. <i>Blood</i> , 1998, 91, 4796-4802.	0.6	33
52	Carboxypeptidase M as a marker of macrophage maturation. <i>Immunological Reviews</i> , 1998, 161, 119-127.	2.8	29
53	A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas. <i>Leukemia and Lymphoma</i> , 2010, 51, 447-455.	0.6	29
54	<i>EZH2</i> mutations and impact on clinical outcome: an analysis in 1,604 patients with newly diagnosed acute myeloid leukemia. <i>Haematologica</i> , 2020, 105, e228-e231.	1.7	29

#	ARTICLE	IF	CITATIONS
55	Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2021, 11, 164.	2.8	29
56	Cytokine repertoire during maturation of monocytes to macrophages within spheroids of malignant and non-malignant urothelial cell lines. , 1998, 78, 648-653.		28
57	Measurements of immature platelets with haematology analysers are of limited value to separate immune thrombocytopenia from bone marrow failure. <i>British Journal of Haematology</i> , 2017, 177, 612-619.	1.2	28
58	Elimination of activated but not resting primary human CD4 and CD8 T cells by Fas ligand (FasL/CD95L)-expressing Killer-dendritic cells. <i>Immunobiology</i> , 2004, 208, 463-475.	0.8	25
59	Survey and analysis of the efficacy and prescription pattern of sorafenib in patients with acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2012, 53, 1062-1067.	0.6	23
60	Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV. <i>Leukemia</i> , 2018, 32, 1222-1228.	3.3	22
61	Blood counts in adult and elderly individuals: defining the norms over eight decades of life. <i>British Journal of Haematology</i> , 2020, 189, 777-789.	1.2	22
62	Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV. <i>Annals of Hematology</i> , 2014, 93, 1167-1176.	0.8	21
63	Dual-targeting triplebody 33-16-123 (SPM-2) mediates effective redirected lysis of primary blasts from patients with a broad range of AML subtypes in combination with natural killer cells. <i>Oncolmmunology</i> , 2018, 7, e1472195.	2.1	21
64	Impact of <i>PTPN11</i> mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia. <i>Blood Advances</i> , 2021, 5, 3279-3289.	2.5	21
65	Genomic Organization of the Human Gene HEP27: Alternative Promoter Usage in HepG2 Cells and Monocyte-Derived Dendritic Cells. <i>Genomics</i> , 2002, 79, 608-615.	1.3	20
66	Structure of the human carboxypeptidase M gene. Identification of a proximal GC-rich promoter and a unique distal promoter that consists of repetitive elements. <i>Gene</i> , 2002, 284, 189-202.	1.0	18
67	Indirect determination of hematology reference intervals in adult patients on Beckman Coulter UniCell DxH 800 and Abbott CELL-DYN Sapphire devices. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019, 57, 730-739.	1.4	18
68	Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV. <i>Haematologica</i> , 2019, 104, 955-962.	1.7	18
69	Differential impact of <i>IDH1</i> / <i>IDH2</i> mutational subclasses on outcome in adult AML: results from a large multicenter study. <i>Blood Advances</i> , 2022, 6, 1394-1405.	2.5	17
70	Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations. <i>Journal of Hematology and Oncology</i> , 2022, 15, 60.	6.9	17
71	Prophylactic Application of Nebulized Liposomal Amphotericin B in Hematologic Patients with Neutropenia. <i>Onkologie</i> , 2011, 34, 254-258.	1.1	16
72	The JAM-assay: optimized conditions to determine death-receptor-mediated apoptosis. <i>Methods</i> , 2003, 31, 127-134.	1.9	15

#	ARTICLE	IF	CITATIONS
73	Amphotericin B deoxycholate: no significant advantage of a 24 h over a 6 h infusion schedule. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 60, 180-182.	1.3	11
74	Treatment of B cell lymphoma with chemotherapy plus rituximab: a survival benefit can be demonstrated in the routine data of a regional cancer registry. <i>Annals of Hematology</i> , 2012, 91, 561-570.	0.8	11
75	Rapid monitoring of immune reconstitution after allogeneic stem cell transplantation – a comparison of different assays for the detection of cytomegalovirus-specific T cells. <i>European Journal of Haematology</i> , 2013, 91, 534-545.	1.1	10
76	Rationing Cancer Care: A Survey Among the Members of the German Society of Hematology and Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 658-665.	2.3	10
77	Reproducible measurable residual disease detection by multiparametric flow cytometry in acute myeloid leukemia. <i>Leukemia</i> , 2022, 36, 2208-2217.	3.3	8
78	Aspergillus-specific nested PCR from the site of infection is superior to testing concurrent blood samples in immunocompromised patients with suspected invasive aspergillosis. <i>Mycoses</i> , 2019, 62, 1035-1042.	1.8	7
79	Loss-of-Function Mutations of BCOR Are an Independent Marker of Adverse Outcomes in Intensively Treated Patients with Acute Myeloid Leukemia. <i>Cancers</i> , 2021, 13, 2095.	1.7	7
80	Final Evaluation of Randomized CML-Study IV: 10-Year Survival and Evolution of Terminal Phase. <i>Blood</i> , 2017, 130, 897-897.	0.6	7
81	Imatinib in Chronic Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2007, 356, 1780-1780.	13.9	5
82	Ifosfamide, epirubicin, and etoposide (IEV) mobilize peripheral blood stem cells more efficiently than cyclophosphamide/etoposide. <i>Annals of Hematology</i> , 2007, 86, 575-581.	0.8	5
83	Three-dimensional co-culture of human monocytes and macrophages with tumor cells: Analysis of macrophage differentiation and activation. , 1996, 66, 645.		5
84	On Its Way to Primetime: Artificial Intelligence in Flow Cytometry Diagnostics. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2020, 97, 990-993.	1.1	4
85	Optimization of Imatinib Therapy by Combination. 5 Year Survival and Response Results of the Pilot Phase of the Randomized German CML STUDY IV.. <i>Blood</i> , 2009, 114, 862-862.	0.6	4
86	Reticulated platelets – clinical application and future perspectives. <i>Journal of Laboratory Medicine</i> , 2020, 44, 241-253.	1.1	4
87	Adoptive therapy with monocyte-derived macrophages in the setting of high-dose chemotherapy and peripheral blood stem cell transplantation. <i>British Journal of Haematology</i> , 2002, 116, 920-922.	1.2	3
88	The effect of erythrocyte lysing reagents on enumeration of leukocyte subpopulations compared with a no-lyse-wash protocol. <i>International Journal of Laboratory Hematology</i> , 2021, 43, 939-947.	0.7	2
89	Retinoic Acid Inhibits Monocyte to Macrophage Survival and Differentiation. <i>Blood</i> , 1998, 91, 4796-4802.	0.6	1
90	Real Life Experience with ATRA-Arsenic Trioxide Based Regimen in Acute Promyelocytic Leukemia - Updated Results of the Prospective German Intergroup Napoleon Registry. <i>Blood</i> , 2016, 128, 2815-2815.	0.6	1

#	ARTICLE	IF	CITATIONS
91	Pioglitazone and Rofecoxib Combined with Angiostatically Scheduled Capecitabine in Far-Advanced Hepatobiliary Carcinoma. , 2010, , 341-352.		0